Navirel (Vinorelbine)

Vinorelbine, the active ingredient in Navirel, is a Vinca alkaloid presented as a sterile solution for intravenous use. It is employed in the treatment of certain solid tumours, notably non‑small cell lung cancer and metastatic breast cancer, in adult patients. It is administered by a healthcare professional under controlled conditions.

GNH USA supplies Navirel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality for oncology treatment programs.

Vinorelbine is a chemotherapy agent that interferes with cell division and is used in the management of solid tumours, especially within the lung and breast cancer treatment pathways.

- Non‑small cell lung cancer: used as first‑line or second‑line therapy to reduce tumour burden and improve progression‑free survival. - Metastatic breast cancer: employed after anthracycline failure to achieve disease control and prolong survival. - Malignant pleural effusion associated with lung cancer: administered intrapleurally to alleviate fluid accumulation and improve respiratory comfort.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: gastrointestinal upset commonly reported. - Fatigue: persistent tiredness affecting daily activities. - Alopecia: hair loss that may be temporary. - Constipation: reduced bowel movements. - Mild peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe pulmonary toxicity: dyspnoea or interstitial pneumonitis. - Anaphylactic reactions: sudden severe allergic response. - Cardiac dysfunction: reduced ejection fraction or arrhythmias. - Severe peripheral neuropathy: persistent loss of sensation. - Thrombocytopenia: low platelet count leading to bleeding.

Before initiating Vinorelbine therapy, several safety considerations should be observed.

- Monitor blood counts: perform regular CBC to detect neutropenia and thrombocytopenia. - Assess liver function: adjust dosing in hepatic impairment. - Evaluate renal function: use caution in severe renal insufficiency. - Check for hypersensitivity: discontinue if severe allergic reaction occurs. - Pregnancy and lactation: avoid unless benefits outweigh potential fetal or infant risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with other medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase vinorelbine plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Concurrent myelosuppressive agents: heighten risk of severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance bleeding tendency. - Antiemetics containing CYP3A4 substrates: monitor for altered metabolism. - Diuretics: watch for electrolyte disturbances that could exacerbate toxicity.